Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review - Wikidata - awgldk - TriplyDB

Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review

Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review

http://www.wikidata.org/entity/Q28080289

about

Epidemiology of ischemic heart disease in HIV.Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.Atazanavir sulfate + cobicistat for the treatment of HIV infection.Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.

P2860

Q38629009-7A64EB74-2B9F-4E1F-9910-225271080FBE Q40129344-0C7CAB99-E212-42D4-AFBC-C4A79B62663E Q40237526-2A308295-A4F8-4131-9F4A-2231A1E60C34 Q46016007-F525EFE9-A355-4665-9573-971E4747F982

P2860

Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review

http://www.wikidata.org/entity/Q28080289

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Atazanavir and Cardiovascular ...... Patients: A Systematic Review

@ast

Atazanavir and Cardiovascular ...... Patients: A Systematic Review

@en

Atazanavir and Cardiovascular ...... Patients: A Systematic Review

@nl

type

label

Atazanavir and Cardiovascular ...... Patients: A Systematic Review

@ast

Atazanavir and Cardiovascular ...... Patients: A Systematic Review

@en

Atazanavir and Cardiovascular ...... Patients: A Systematic Review

@nl

prefLabel

Atazanavir and Cardiovascular ...... Patients: A Systematic Review

@ast

Atazanavir and Cardiovascular ...... Patients: A Systematic Review

@en

Atazanavir and Cardiovascular ...... Patients: A Systematic Review

@nl

P1433

Q28080289-200ACA58-EC83-4B30-8F53-A51EC8D6F6B9

P1476

Q28080289-62348930-6E21-48D5-B06A-A7273F11B60C

P2093

Q28080289-5C21EDDF-A355-4FDF-AFF7-F455CD9796AA

Q28080289-5F01FBEC-FA39-41C5-8E92-135427680B9E

Q28080289-63D83E45-C9B2-42F6-A75C-54993EF70DB9

Q28080289-991A1560-FE90-464C-935C-EFF310B1EB5A

P2860

Q28080289-0391525B-F184-4295-9BC2-1B422EE346E1

Q28080289-0EE695DC-7C66-4EC4-A290-0F4D72E4EE66

Q28080289-2651E5BA-C31C-4C77-99E4-A3D5C83C1D52

Q28080289-308FAF34-A3EB-4874-A35D-44E229BA5148

Q28080289-40870B08-2541-41C3-BF49-EDE05D47DB26

Q28080289-4A6FBFC6-049F-479D-BE3A-557F555CD4B2

Q28080289-4FFDEE82-A339-4222-8F1E-E2C04D93E5FE

Q28080289-5234CE37-7AA6-412B-A47E-3946E492FA16

Q28080289-583ED8FB-5C08-45AA-857C-C1FE8B31E38F

Q28080289-5CEF6876-C269-45B2-9BF3-AE1B6ADC3BBD

P2888

Q28080289-C19BA0BC-2C37-4969-ABC8-9378F4E0746B

P304

Q28080289-C0114143-155B-4578-AF92-2CB69123C559

P31

Q28080289-38213DC9-7E4F-4A16-B80C-817E892E065D

Q28080289-73EF52C9-B51C-4E42-B935-06141C039376

P3181

Q28080289-20D7D8BD-B5D6-42B8-B370-3685742333F5

P356

Q28080289-8C15C7D5-66F0-4AE4-BDA6-CC931E62B456

P407

Q28080289-2C687163-1F89-4FA8-B21B-880D0428A79D

P433

Q28080289-8F0C63D7-9701-4E38-A508-2215973EA0C3

P478

Q28080289-975B6B28-B7BF-4827-830D-95BCA1AF3F83

P50

Q28080289-EE8BD103-8606-461C-9D82-22728F90D839

P577

Q28080289-5E646C01-2D7E-4B53-A72A-984306BB60FF

P6179

Q28080289-58E6FDD7-D954-4986-A00B-F6E8DFD507D6

P698

Q28080289-738937BF-C3EC-4825-B773-AB26023CC18F

P932

Q28080289-1AF97917-79BC-4C89-8D53-C8D784D7875F

P3181

P356

S40121-016-0132-Z

P1433

Infectious diseases and therapy

P1476

Atazanavir and Cardiovascular ...... Patients: A Systematic Review

@en

P2093

Cecilia Shikuma

http://www.w3.org/2001/XMLSchema#string

Corey Ritchings

http://www.w3.org/2001/XMLSchema#string

Lisa Rosenblatt

http://www.w3.org/2001/XMLSchema#string

Muxing Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Association of serum bilirubin concentration with risk of coronary artery disease.

Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels.

Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients.

Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study.

Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review

Gilbert's syndrome and the risk of death: a population-based cohort study.

P2888

s40121-016-0132-z

P304

473-489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

3323371

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S40121-016-0132-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1030498754

http://www.w3.org/2001/XMLSchema#string

P698

27677263

http://www.w3.org/2001/XMLSchema#string

P932

5125135

http://www.w3.org/2001/XMLSchema#string